Overcoming Site Challenges in Oncology Trials – An interview with Penny Chipman
In this interview Penny Chipman, Manager of the Clinical Research Program at the Gerald Bronfman Centre for Clinical Research in…
Importance of Strategic Advisors & Strong Leadership
In my last post we looked at the need for a visionary drug development plan. Today’s post will outline the…
Importance of having a visionary drug development plan
In my last post we looked at the first of three essential assets that your team should look to acquire…
First Essential Asset for Successful Oncology Drug Development
Developing oncology compounds is a constantly evolving process, and with the dramatic rise in costs, making every step count is…
Reverse Feasibility in Action – Transcript of interview with Dr. Quincy Chu
In this interview, Dr. Quincy Chu, Medical Oncologist at the Cross Cancer Institute in Edmonton Alberta, discusses the ways in…
Value of Canadian oncology centers for early phase trials – Transcript of interview with Dr. Stephen Welch
Given the increased focus on speed of activation for oncology studies, sponsors are under pressure to select top-performing investigative sites…
How to double your oncology enrolment targets
Back in June of 2011, a leading U.S. biotech company, currently developing multiple therapeutic candidates, was planning a Phase I/II…
How to speed up site start-up by 50%: Part 2 – Contract Negotiation
Like patient consent forms, site Clinical Trial Agreements (CTA) have become increasingly complex, making their review a major roadblock to…
How to speed up site start-up by 50% Step 1: Reverse Feasibility Approach
Data from the Journal of Clinical Oncology suggests that the average U.S. site start-up time is approximately 36 weeks**. In…
Why Canada is well suited for YOUR oncology clinical trials
To make it to the winner’s circle in this industry, you must know your strengths and leverage them to maximize…